A New York jury has delivered the first plaintiff's verdict recorded in the multidistrict litigation over the anti-bone loss drug Fosamax, deciding Merck should pay $8 million for present and future pain and suffering to Shirley Boles, one of some 900 plaintiffs who filed suit in state and federal courts, alleging Fosamax caused jawbone deterioration. The case is one of the bellwether cases selected by the court in In Re: Fosamax Products Liability Litigation. The first bellwether ended in a defense verdict.
N.Y. Jury Delivers First Plaintiff's Win in Fosamax Litigation
New York Law Journal
June 28, 2010